Trial Profile
Safety and pharmacokinetics of JNJ-53718678 in healthy adult subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Mar 2017
Price :
$35
*
At a glance
- Drugs Rilematovir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; First in man; Pharmacokinetics
- 14 Mar 2017 New trial record
- 25 Feb 2017 Results published in the Clinical Pharmacokinetics